Form SCHEDULE 13D/A enVVeno Medical Corp Filed by: Braeden Lichti
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 |
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
|
enVVeno Medical Corp (Name of Issuer) |
Common Stock, par value $0.00001 per share (Title of Class of Securities) |
(CUSIP Number) |
Ross. D. Carmel, Esq. 1185 Avenue of the Americas, 31st Floor New York, NY, 10036 (212) 930-9700 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) |
09/11/2026 (Date of Event Which Requires Filing of This Statement) |
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the
Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other
provisions of the Act (however, see the Notes).
SCHEDULE 13D
|
| CUSIP No. |
| 1 |
Name of reporting person
Braeden Lichti | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
PF | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
CANADA (FEDERAL LEVEL)
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
0.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.00 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
On September 11, 2026, Braeden Lichti sold all of his previously owned shares of enVVeno Medical Corp ("Issuer")'s common stock, par value $0.00001 per share ("Common Stock") and no longer owns any shares of Common Stock of the Issuer. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for Mr. Lichti.
SCHEDULE 13D
 |
| CUSIP No. |
| 1 |
Name of reporting person
Northstrive Fund II LP | ||||||||
| 2 | Check the appropriate box if a member of a Group (See Instructions)
(a)
(b) | ||||||||
| 3 | SEC use only | ||||||||
| 4 |
Source of funds (See Instructions)
WC | ||||||||
| 5 |
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
| ||||||||
| 6 | Citizenship or place of organization
DELAWARE
| ||||||||
| Number of Shares Beneficially Owned by Each Reporting Person With: |
| ||||||||
| 11 | Aggregate amount beneficially owned by each reporting person
0.00 | ||||||||
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
| ||||||||
| 13 | Percent of class represented by amount in Row (11)
0.00 % | ||||||||
| 14 | Type of Reporting Person (See Instructions)
IN |
Comment for Type of Reporting Person:
From September 11, 2026 to September 14, 2026, Northstrive Fund II LP sold all of its previously owned shares of the Common Stock, and no longer owns any shares of Common Stock. Accordingly, this filing is the final amendment to the Schedule 13D and constitutes an exit filing for Northstrive Fund II LP.
SCHEDULE 13D
|
| Item 1. | Security and Issuer |
| (a) | Title of Class of Securities:
Common Stock, par value $0.00001 per share |
| (b) | Name of Issuer:
enVVeno Medical Corp |
| (c) | Address of Issuer's Principal Executive Offices:
70 Doppler, Irvine,
CALIFORNIA
, 92618. |
| Item 2. | Identity and Background |
| (a) | This Schedule 13D is filed jointly by Northstrive Fund II LP ("Northstrive Fund") and Braeden Lichti (together with Northstrive Fund, the "Reporting Persons"). The shares of Common Stock are held by Northstrive Fund and Mr. Braeden Lichti. Braeden Lichti is, as of the date of this Schedule 13D/A filing, the Manager of Northstrive Fund. |
| (b) | The address of each of Northstrive Fund and Mr. Lichti is 120 Newport Center Drive, Newport Beach, CA 92660. |
| (c) | Northstrive Fund is principally engaged in the business of investments into private and public securities. Mr. Lichti is principally engaged as the Chief Executive Officer of Northstrive Companies Inc., a California based management, advisory and investment company. |
| (d) | None of the Reporting Persons have, during the last five years, been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws. |
| (e) | None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree, or final order enjoining future violations of, or prohibiting or mandating activities subject to, Federal or state securities laws or finding any violation with respect to such laws. |
| (f) | Northstrive Fund is a Delaware limited partnership. Mr. Lichti is a citizen of Canada. |
| Item 3. | Source and Amount of Funds or Other Consideration |
The information set forth in Item 4 is incorporated by reference herein. Mr. Lichti previously used personal funds to purchase his previously owned Common Stock. Northstrive Fund previously used working capital as the source of funds for the purchase of its previously owned Common Stock. | |
| Item 4. | Purpose of Transaction |
On September 11, 2026, Braeden Lichti sold all of his previously owned shares of the Issuer's Common Stock and no longer owns any shares of Common Stock. From September 11, 2026 to September 14, 2026, NorthStrive Fund II LP sold all of its previously owned shares of the Common Stock, and no longer owns any shares of Common Stock. Previously, the Reporting Persons herein filed a Schedule 13D with the U.S. Securities and Exchange Commission on February 20, 2026 ("Schedule 13D"), which reported the number of shares held by each reporting person as of February 20, 2026. This Schedule 13D/A filing is the final amendment to the Schedule 13D and constitutes an exit filing for Braeden Lichti and NorthStrive Fund II LP. | |
| Item 5. | Interest in Securities of the Issuer |
| (a) | For Northstrive Fund II LP, none as of February 11, 2026. For Braeden Lichti, none as of February 14, 2026. |
| (b) | Sole power to vote or to direct the vote: Northstrive Fund II LP: 0 shares Braeden Lichti: 13,0 shares Shared power to vote or to direct the vote: Northstrive Fund II LP: 0 shares Braeden Lichti: 0 shares Sole power to dispose or to direct the disposition of: Northstrive Fund II LP: 0 shares Braeden Lichti: 0 shares Shared power to dispose or to direct the disposition: Northstrive Fund II LP: 0 shares Braeden Lichti: 0 shares |
| (c) | The information set forth in Item 3 above is incorporated herein by reference. |
| (d) | Not applicable. |
| (e) | Not applicable. |
| Item 6. | Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer |
The information in Items 3 and 4 are incorporated herein by reference. |
| SIGNATURE | |
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
|
|
|
|